Rhythm (RYTM) Q1 2026 Earnings Call Summary
Rhythm (RYTM) reported Q1 2026 earnings with $60.1 million in global net product sales, a 5% sequential increase from Q4 2025. International revenue grew by 27% to $23.2 million, driven by markets in Germany, France, Saudi Arabia, and Greece. The company noted steady U.S. prescription growth for its Bardet-Biedl syndrome franchise and a successful launch of its acquired hypothalamic obesity treatment.
Tickers: $RYTM
Topics: international_growth patient_growth product_launch revenue